TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Autor: Zom GG; Department of Immunohematology and Blood Transfusion, Section Tumorimmunology, Leiden University Medical Center, Leiden, The Netherlands., Welters MJ; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Loof NM; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Goedemans R; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Lougheed S; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands., Valentijn RR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Zandvliet ML; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Meeuwenoord NJ; Leiden Institute of Chemistry, University of Leiden, Leiden, The Netherlands., Melief CJ; Department of Immunohematology and Blood Transfusion, Section Tumorimmunology, Leiden University Medical Center, Leiden, The Netherlands.; ISA Pharmaceuticals BV, Leiden, The Netherlands., de Gruijl TD; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands., Van der Marel GA; Leiden Institute of Chemistry, University of Leiden, Leiden, The Netherlands., Filippov DV; Leiden Institute of Chemistry, University of Leiden, Leiden, The Netherlands., Ossendorp F; Department of Immunohematology and Blood Transfusion, Section Tumorimmunology, Leiden University Medical Center, Leiden, The Netherlands., Van der Burg SH; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.

Publikováno v: Oncotarget [Oncotarget] 2016 Oct 11; Vol. 7 (41), pp. 67087-67100.